Leadman(SZ:300289)2024-04-25 07:55Financial Performance - The company's revenue for Q1 2024 was ¥94,624,115.26, a decrease of 12.51% compared to ¥108,150,382.74 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥2,705,087.82, representing a decline of 132.61% from a profit of ¥8,296,310.96 in the previous year[4] - The net cash flow from operating activities decreased by 69.06%, amounting to ¥8,512,332.16 compared to ¥27,508,461.89 in the prior year[4] - The company achieved operating revenue of ¥94,624,100, a decrease of 12.51% year-on-year, with a net profit attributable to shareholders of -¥2,705,100[18] - The revenue from in vitro diagnostic reagents was ¥74,948,600, down 15.84%, accounting for 79.21% of total revenue[18] - The company's net profit margin decreased, with a net loss of CNY 2,482,328.36 reported for the current period[25] - The net profit for the first quarter of 2024 was -1,957,415.15 CNY, compared to a net profit of 10,109,371.69 CNY in the same period last year, indicating a significant decline[26] - The operating profit for the first quarter was -262,599.44 CNY, while the previous year's operating profit was 12,230,679.66 CNY, reflecting a substantial decrease[26] Cash Flow and Assets - The total assets at the end of the reporting period were ¥1,906,543,922.72, down 1.64% from ¥1,938,398,607.33 at the end of the previous year[4] - The cash and cash equivalents increased by 30.37%, amounting to ¥736,641,439.29, mainly due to the redemption of maturing financial assets[10] - The company reported cash flow from investing activities of 163,290,894.40 CNY, a significant increase compared to -41,878,241.16 CNY in the same quarter last year[29] - The total cash and cash equivalents at the end of the quarter amounted to 736,106,679.59 CNY, compared to 781,125,070.33 CNY at the end of the previous year[30] - The cash inflow from operating activities totaled 130,917,998.72 CNY, compared to 142,616,871.69 CNY in the same quarter last year[29] - The company incurred total operating cash outflows of 122,405,666.56 CNY, which is an increase from 115,108,409.80 CNY in the previous year[29] Liabilities and Shareholder Information - The total liabilities decreased to CNY 102,921,910.43 from CNY 133,769,179.89, a reduction of 23.1%[24] - The total number of ordinary shareholders at the end of the reporting period was 20,311, with the largest shareholder holding 46.35% of the shares[15] - The company’s largest shareholder, Guangzhou High-tech Zone Technology Holdings Group Co., Ltd., holds 252,133,152 shares, with 126,213,152 shares under lock-up[15] Operational Changes and Developments - The company reported a significant reduction in employee compensation payable, which decreased by 90.29% to ¥940,004.05, as the year-end bonuses from the previous year were paid out[10] - The company added three new invention patents during the reporting period, focusing on rapid quantitative detection of various biomarkers[19] - The company completed the renewal of its Medical Device Production License, extending the validity until May 28, 2029[19] - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[25] - The company did not report any new product launches or significant market expansion strategies during this quarter[31] Income and Expense Analysis - The company reported a significant decrease in other income, which was ¥797,039.80, down 70.03% from ¥2,659,038.82 in the previous year[12] - The fair value change income increased by 230.71%, reaching ¥497,319.48 compared to a loss of ¥380,468.51 in the same period last year[12] - The revenue from biochemical raw materials increased by 19.12% to ¥6,432,000, accounting for 6.80% of total revenue[18] - Total operating costs for Q1 2024 were CNY 97,106,443.62, slightly down from CNY 97,647,698.37 in the previous period[25]